Open main menu

Psychiatrienet β

Bupropion-venlafaxine

Revision as of 14:12, 1 September 2009 by Verena (talk | contribs)
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from bupropion to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Gradually reduce dosage of bupropion to a maximum of 150 mg/day.
  • When a dosage of 150 mg/day is reached, stop administration.[3]
Eenrichtingbord.png Start venlafaxine
  • Day 1-7: a wash-out period of at least one week is necessary.
  • Day 8: start venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day.
Infobord.png More information
  • By considering a wash-out period of one week (5 times the elimination time of bupropion and its metabolites) it is assured that all bupropion has left the body and no drug interactions occur.
  • Bupropion slows the metabolism of venlafaxine by CYP2D6.
  1. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. ↑ Kennedy et al, Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.. J Clin Psychiatry 2002 March;63(3):181-6.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Bupropion-venlafaxine&oldid=3692"